A Multi-center, Open Label, Single-arm Study to Investigate the Safety and Efficacy of Daily Oral Administration of 2 mg Dienogest Tablets for the Treatment of Endometriosis in Adolescents Over a Treatment Period of 52 Weeks.

Trial Profile

A Multi-center, Open Label, Single-arm Study to Investigate the Safety and Efficacy of Daily Oral Administration of 2 mg Dienogest Tablets for the Treatment of Endometriosis in Adolescents Over a Treatment Period of 52 Weeks.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2015

At a glance

  • Drugs Dienogest (Primary)
  • Indications Endometriosis
  • Focus Adverse reactions
  • Acronyms VISADO
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 03 Jun 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 04 Dec 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Sep 2013 Planned end date changed from 1 Sep 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top